A detailed history of Advisor Group Holdings, Inc. transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 20,575 shares of AUTL stock, worth $61,519. This represents 0.0% of its overall portfolio holdings.

Number of Shares
20,575
Previous 20,575 -0.0%
Holding current value
$61,519
Previous $71,000 4.23%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$3.33 - $5.68 $333 - $568
100 Added 0.49%
20,575 $71,000
Q1 2024

May 10, 2024

SELL
$5.39 - $7.29 $7,346 - $9,936
-1,363 Reduced 6.24%
20,475 $130,000
Q4 2023

Feb 12, 2024

BUY
$2.13 - $6.63 $7,589 - $23,622
3,563 Added 19.5%
21,838 $140,000
Q3 2023

Nov 13, 2023

BUY
$2.32 - $3.36 $2,378 - $3,444
1,025 Added 5.94%
18,275 $42,000
Q2 2023

Aug 10, 2023

BUY
$1.64 - $3.21 $533 - $1,043
325 Added 1.92%
17,250 $41,000
Q4 2022

Feb 10, 2023

BUY
$1.74 - $3.27 $28,579 - $53,709
16,425 Added 3285.0%
16,925 $32,000
Q1 2022

May 04, 2022

BUY
$3.52 - $5.46 $1,408 - $2,184
400 Added 400.0%
500 $2,000
Q2 2021

Aug 02, 2021

SELL
$4.78 - $7.96 $27,485 - $45,770
-5,750 Reduced 98.29%
100 $1,000
Q1 2021

May 13, 2021

BUY
$5.49 - $9.36 $4,117 - $7,020
750 Added 14.71%
5,850 $34,000
Q4 2020

Feb 10, 2021

BUY
$8.13 - $12.79 $813 - $1,279
100 Added 2.0%
5,100 $46,000
Q3 2020

Nov 12, 2020

SELL
$11.64 - $16.3 $29,100 - $40,750
-2,500 Reduced 33.33%
5,000 $58,000
Q2 2020

Aug 14, 2020

SELL
$5.38 - $16.14 $3,766 - $11,298
-700 Reduced 8.54%
7,500 $120,000
Q1 2020

May 18, 2020

BUY
$4.2 - $13.0 $34,440 - $106,600
8,200 New
8,200 $46,000

Others Institutions Holding AUTL

About Autolus Therapeutics plc


  • Ticker AUTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,909,800
  • Market Cap $272M
  • Description
  • Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...
More about AUTL
Track This Portfolio

Track Advisor Group Holdings, Inc. Portfolio

Follow Advisor Group Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.